News
VANI
1.255
+1.21%
0.015
Weekly Report: what happened at VANI last week (0914-0918)?
Weekly Report · 09/21 09:04
Vivani Medical Announces Merger Deal Involving Cortigent
TipRanks · 09/16 20:54
Weekly Report: what happened at VANI last week (0907-0911)?
Weekly Report · 09/14 09:04
Weekly Report: what happened at VANI last week (0831-0904)?
Weekly Report · 09/07 09:04
Weekly Report: what happened at VANI last week (0824-0828)?
Weekly Report · 08/31 09:04
Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly?
NASDAQ · 08/29 23:35
Weekly Report: what happened at VANI last week (0817-0821)?
Weekly Report · 08/24 09:04
Analysts Offer Insights on Healthcare Companies: Vivani Medical (VANI) and InspireMD (NSPR)
TipRanks · 08/18 14:00
Vivani Medical Updates Investors with Regulation FD Presentation
TipRanks · 08/17 12:29
Weekly Report: what happened at VANI last week (0810-0814)?
Weekly Report · 08/17 09:04
Lake Street Remains a Buy on Vivani Medical (VANI)
TipRanks · 08/14 13:15
Vivani Speeds Semaglutide Implant Trial Enrollment Completion
TipRanks · 08/13 21:24
Vivani Medical Q2 EPS $(0.07) Beats $(0.08) Estimate
Benzinga · 08/13 20:21
Vivani Medical GAAP EPS of -$0.07 beats by $0.01
Seeking Alpha · 08/13 20:20
Press Release: Vivani Medical Reports Second -2-
Dow Jones · 08/13 20:05
Vivani Medical: Q2 Earnings Snapshot
Barchart · 08/13 15:56
Weekly Report: what happened at VANI last week (0803-0807)?
Weekly Report · 08/10 09:04
Vivani Medical announces full enrollment, initial dosing in SLIM-1 trial
TipRanks · 08/06 14:01
Vivani Completes Enrollment in SLIM-1 Semaglutide Implant Trial
TipRanks · 08/06 12:54
Weekly Report: what happened at VANI last week (0727-0731)?
Weekly Report · 08/03 09:04
More
Webull provides a variety of real-time VANI stock news. You can receive the latest news about Vivani Medical through multiple platforms. This information may help you make smarter investment decisions.
About VANI
Vivani Medical, Inc. is a clinical-stage biopharmaceutical company, developing miniature, ultra-long-acting drug implants. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its segments include the Biopharm Division and Neurostimulation Division. Its pipeline includes NPM-139, NPM-133, NPM-115 and OKV-119. NPM-139 is a six-month, semaglutide implant under development for the treatment of chronic weight management. NPM-115 is an exenatide-based implant candidate also under development for the treatment of chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed for once or twice-yearly administration of medication.